| Literature DB >> 33681394 |
Khai-Hoan Nguyen-Phuoc1,2,3, Ngoc-Diem Duong1,2,4,3, Thach Van Phan1,2, Kim-Yen Thi Do4, Nguyet-Thu Thi Nguyen4, Thuoc Linh Tran1,2, Hieu Tran-Van1,2.
Abstract
Acute Hepatopancreatic Necrosis Disease (AHPND) is a newly emerging shrimp disease with mortality up to 100 percent caused by Vibrio parahaemolyticus which carries a plasmid encoding for two toxins, ToxA and ToxB. In 2013, the Global Aquaculture Alliance (GAA) estimated shrimp farming decline in Asia accounted for 1-billion US dollar lost. Currently, diagnosis using PCR method does not meet the demand of in situ detection, which is based on antigen-antibody interaction, has not been developed yet. In this present study, we proceeded to create the toxin and its antibody for lateral flow development. First, recombinant toxin ToxA was generated by gene manipulation. After that, purified ToxA was used to immunize rabbits. Finally, antisera from rabbits and protein-A purified antibodies were evaluated for titer, specificity, and detection threshold. Results showed that recombinant ToxA was overexpressed in soluble fraction at 37oC with 1mM IPTG. Purification by affinity chromatography was able to isolate recombinant ToxA with the purity up to 94.49%. In ELISA experiment, the immunized antisera reached a titer of up to 1/5,210,000 with 1µg/ml of antigen, and detection threshold was 100ng recombinant toxin. After purification, the detection threshold of purified polyclonal antibodies was 25ng toxin per dot. These results laid a groundwork for the development of AHPND detection kit based on antigen - antibody interactions.Entities:
Keywords: AHPND; Polyclonal antibodies; Recombinant toxin; ToxA; Immuno-interactions; Vibrio parahaemolyticus
Year: 2021 PMID: 33681394 PMCID: PMC7936389 DOI: 10.22099/mbrc.2020.38774.1561
Source DB: PubMed Journal: Mol Biol Res Commun ISSN: 2322-181X